{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:55:31Z","timestamp":1793163331145,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106078","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:28:13Z","timestamp":1771262893000},"page":"106078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-9297","authenticated-orcid":false,"given":"K.","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-9612","authenticated-orcid":false,"given":"R.","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-4454","authenticated-orcid":false,"given":"H.","family":"Borghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-9465","authenticated-orcid":false,"given":"A.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Spigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gurpide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-4704","authenticated-orcid":false,"given":"R.A.","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-0380","authenticated-orcid":false,"given":"S.A.","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5992-5838","authenticated-orcid":false,"given":"M.","family":"Cerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-0753","authenticated-orcid":false,"given":"D.M.","family":"Greenawalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2026.106078_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/OP.21.00305","article-title":"Advances in immunotherapy and implications for current practice in non-small-cell lung cancer","volume":"17","author":"Steuer","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2026.106078_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2018.07.127","article-title":"The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies","volume":"103","author":"Simonsen","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106078_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106078_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106078_bib7","doi-asserted-by":"crossref","first-page":"S1243","DOI":"10.1016\/j.annonc.2024.08.2295","article-title":"Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: results from the randomized phase II RELATIVITY-104 study (LBA53)","volume":"35","author":"Girard","year":"2024","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106078_bib9","doi-asserted-by":"crossref","first-page":"CT116","DOI":"10.1158\/1538-7445.AM2017-CT116","article-title":"BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1\/2a trial (abstract CT116)","volume":"77","author":"Siu","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2026.106078_bib10","first-page":"89","article-title":"O41 Preliminary antitumor and immunomodulatory activity of BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, in combination with nivolumab in patients with advanced cancers","volume":"5","author":"Luke","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106078_bib11","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1158\/1078-0432.CCR-24-0439","article-title":"Phase 1\/2 study of the indoleamine 2,3-dioxygenase 1 inhibitor linrodostat mesylate combined with nivolumab or nivolumab and ipilimumab in advanced solid tumors or hematologic malignancies","volume":"31","author":"Luke","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106078_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","article-title":"Dasatinib changes immune cell profiles concomitant with reduced tumor growth in several murine solid tumor models","volume":"5","author":"Hekim","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106078_bib13","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/0008-5472.CAN-24-2772","article-title":"Dasatinib remodels the tumor microenvironment and sensitizes small cell lung cancer to immunotherapy","volume":"85","author":"Redin","year":"2025","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106078_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav2437","article-title":"Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy","volume":"5","author":"Tu","year":"2019","journal-title":"Sci Adv"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106078_bib15","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106078_bib16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity","volume":"122","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106078_bib17","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1080\/10428194.2021.1889536","article-title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","volume":"62","author":"Mart\u00ednez-L\u00f3pez","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.esmoop.2026.106078_bib18","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106078_bib20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106078_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106078_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med"},{"issue":"7691","key":"10.1016\/j.esmoop.2026.106078_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106078_bib24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106078_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005780","article-title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","volume":"10","author":"Choueiri","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"21","key":"10.1016\/j.esmoop.2026.106078_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106078_bib27","article-title":"SWOG S2302, PRAGMATICA-LUNG: a prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer","volume":"42","author":"Reckamp","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106078_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106078_bib29","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-023-02385-6","article-title":"Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495\/KeyImPaCT trial interim results","volume":"29","author":"Gutierrez","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.106078_bib30","article-title":"457 KEYNOTE-495\/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (NSCLC)","volume":"9","author":"Gutierrez","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"10.1016\/j.esmoop.2026.106078_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.39","article-title":"NSCLC, metastatic CheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv\/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC (LBA7_PR)","volume":"27","author":"Socinski","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106078_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106078_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106078_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2026.106078_bib37","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106078_bib38","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106078_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001496","article-title":"SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation","volume":"9","author":"Redin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106078_bib40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1164\/rccm.201807-1292OC","article-title":"YES1 Drives lung cancer growth and progression and predicts sensitivity to sasatinib","volume":"200","author":"Garmendia","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106078_bib41","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106078_bib42","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2022.282005","article-title":"Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia","volume":"108","author":"Harrington","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106078_bib45","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jtho.2023.02.016","article-title":"MRTX-500 phase 2 trial: sitravatinib with nivolumab in patients with nonsquamous NSCLC progressing on or after checkpoint inhibitor therapy or chemotherapy","volume":"18","author":"He","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106078_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106078_bib47","first-page":"73","article-title":"Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies (P232)","volume":"4","author":"Lipson","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106078_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106078_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.817548","article-title":"The landscape of immunotherapy resistance in NSCLC","volume":"12","author":"Frisone","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.106078_bib50","first-page":"S808","article-title":"LBA53 \u2013 ELIOS: a multicentre, molecular profi ling study ofpatients (pts) with epidermal growth factor receptor-mutated(EGFRm) advanced NSCLC treated with fi rst-line (1L) osimertinib","volume":"33","author":"Piotrowska","year":"2022","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106078_bib51","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106078_bib52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:12:41Z","timestamp":1777623161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000207"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106078","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106078"}}